Publication date: Feb 01, 2025
The long-term impacts of coronavirus disease 2019 (COVID-19), or post-acute sequelae of COVID-19 (PASC), are especially pertinent for individuals with systemic autoimmune rheumatic diseases, who are at higher risk of developing COVID-19 infection, complications of acute infection, and possibly PASC. Severity of acute COVID-19 infection, female sex, comorbidities, and immunosuppressive medications impact the risk of PASC in this population. The etiology of PASC remains poorly defined, and the diagnosis is clinical, with symptoms that can overlap with those of rheumatic diseases. A better understanding of the physiologic mechanisms could help to more clearly define PASC and to guide the development of targeted treatments.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Sequelae |
| disease | MESH | Coronavirus Disease 2019 |
| disease | MESH | Rheumatic Diseases |
| disease | MESH | post-acute sequelae of COVID-19 |
| disease | MESH | infection |
| disease | IDO | acute infection |
| disease | MESH | etiology |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | Comorbidity |
| disease | IDO | immunosuppression |